Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Fourth-quarter events to watch for big pharma
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Amgen and Astra hope to carve out a place in asthma
Pivotal data are expected soon on tezepelumab, Amgen and Astrazeneca's shot at non-eosinophilic asthma.
Go or no go? A quiet month ahead for US approval verdicts
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
Bristol hopes to Tyk the psoriasis box
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Alzheimer’s catalysts round off a year dominated by Biogen
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
